Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12497355 | 0.79 | KDM4E (0.47) | PTK2KDM4EKMT2APOLBGAA | |
| SCHEMBL4817806 | 0.76 | HPGD (0.53) | KDM4EPOLBMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL13653517 | 0.76 | GAA (0.51) | PTK2KDM4EKMT2AGAATSHR | |
| SCHEMBL15483137 | 0.76 | LMNA (0.41) | PTK2KDM4EKMT2APOLBGAA | |
| SCHEMBL10952765 | 0.74 | NPSR1 (0.53) | KDM4EGAAMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL28046922 | 0.72 | GAA (0.44) | PTK2KDM4EKMT2APOLBGAA | |
| SCHEMBL28463477 | 0.71 | GAA (0.48) | KMT2APOLBGAACYP2C19TSHR | |
| SCHEMBL13966687 | 0.70 | NPC1 (0.53) | KDM4EKMT2APOLBGAAMAPT | |
| SCHEMBL20657015 | 0.69 | HDAC1 (0.46) | KDM4EPOLBMAPT | |
| SCHEMBL247987 | 0.68 | CACNA1B (0.57) | KMT2APOLBMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512143-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150158884-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARM INC (US) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158884-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | PTK2 3453/4885KDM4E 153/4885KMT2A 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.